11.2021

APIM Therapeutics announced today that the first patient has been treated with ATX-101 in the company’s phase I/II ovarian cancer study. The clinical study investigates ATX-101 in combination with platinum-based chemotherapy and comprises two parts: Part 1 is a safety part with dose limiting toxicity as primary endpoint; Part 2 is an efficacy part with progression free survival as primary endpoint. For a copy of the corresponding press release, please follow this link.